Use este identificador para citar ou linkar para este item: http://repo.saocamilo-sp.br:8080/jspui/handle/123456789/2035
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorTorloni, Maria Reginaen_US
dc.contributor.authorSiaulys, Monicaen_US
dc.contributor.authorRiera, Rachelen_US
dc.contributor.authorMartimbianco, Ana Luiza Cabreraen_US
dc.contributor.authorPacheco, Rafael Leiteen_US
dc.contributor.authorLatorraca, Carolina de Oliveira Cruzen_US
dc.contributor.authorWidmer, Marianaen_US
dc.contributor.authorBetran, Ana Pilaren_US
dc.date.accessioned2024-09-16T14:47:11Z-
dc.date.available2024-09-16T14:47:11Z-
dc.date.issued2021-
dc.identifier.citationTorloni, Maria Regina, et al. “Route of oxytocin administration for preventing blood loss at caesarean section: a systematic review with meta-analysis”. BMJ Open, vol. 11, no 9, setembro de 2021, p. e051793. DOI.org (Crossref), https://doi.org/10.1136/bmjopen-2021-051793.en_US
dc.identifier.issn2044-6055-
dc.identifier.urihttp://repo.saocamilo-sp.br:8080/jspui/handle/123456789/2035-
dc.description.abstractObjectives: Assess the effects of different routes of prophylactic oxytocin administration for preventing blood loss at caesarean section (CS). Design: Systematic review and meta-analysis. Methods: Medline, EMBASE, CINAHL, Cochrane Library, BVS, SciELO and Global Index Medicus were searched through 24 May 2020 for randomised controlled trials (RCTs) comparing different routes of prophylactic oxytocin administration during CS. Study selection, data extraction and quality assessment were conducted by two investigators independently. We pooled results in fixed effects meta-analyses and calculated average risk ratio (RR), mean difference (MD) and 95% CI. We used GRADE to assess the overall quality of evidence for each outcome. Results: Three trials (180 women) were included in the review. All studies compared intramyometrial (IMY) versus intravenous oxytocin in women having prelabour CS. IMY compared with intravenous oxytocin administration may result in little or no difference in the incidence of postpartum haemorrhage (RR 0.14, 95% CI 0.01 to 2.70; N=100 participants; 1 RCT), hypotension (RR 1.00, 95% CI 0.29 to 3.45; N=40; 1 RCT), headache (RR 3.00, 95% CI 0.13 to 69.52; N=40; 1 RCT) or facial flushing (RR 0.50, 95% CI 0.05 to 5.08; N=40; 1 RCT); IMY oxytocin may reduce nausea/vomiting (RR 0.13, 95% CI 0.02 to 0.69; N=140; 2 RCTs). We are very uncertain about the effect IMY versus intravenous oxytocin on the need for additional uterotonics (RR 0.82; 95% CI 0.25 to 2.69; N=140; 2 RCTs). IMY oxytocin may reduce blood loss slightly (MD -57.40 mL, 95% CI -101.71 to -13.09; N=40; 1 RCT). Conclusions: There is limited, low to very low certainty evidence on the effects of IMY versus intravenous oxytocin at CS for preventing blood loss. The evidence is insufficient to support choosing one route over another. More trials, including studies that assess intramuscular oxytocin administration, are needed on this relevant question.-
dc.publisherBMJen_US
dc.relation.ispartofBMJ Open, v. 11, n. 9, 2021en_US
dc.subjectEfeitos colaterais e reações adversas relacionados a medicamentosen_US
dc.subjectTerapêuticaen_US
dc.subjectCirurgia geralen_US
dc.titleRoute of oxytocin administration for preventing blood loss at caesarean section: a systematic review with meta-analysisen_US
dc.typeArtigo de Periódicoen_US
dc.identifier.doi10.1136/bmjopen-2021-051793-
Aparece nas coleções:Artigos de Periódicos

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.